---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-25-000030"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:29:54.501658+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M

## Summary
- Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
- Net income $18.2M (incl. $50.3M stock comp) vs net loss $57.5M in 2023.
- Adjusted EBITDA $75.0M vs -$4.4M in 2023; cash $293.1M, up $50M.
- TissueCypher Barrett's Esophagus test reports surged 130% to 20,956; dermatology reports up 17%.
- 2025 revenue guidance $280-295M, below 2024 actual but achieved prior 2025 target a year early.

## SEC filing metadata
- accession: 0001447362-25-000030
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736225000030/0001447362-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736225000030/cstl-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-25-000030
- JSON: https://secwatch.observer/filing/0001447362-25-000030.json
- Plain text: https://secwatch.observer/filing/0001447362-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.